Julian Gillmore (Centre for Amyloidosis and Acute Phase Proteins, University College London, UK) presented recently published work exploring a gene editing approach in humans to treat TTR-related amyloidosis disease, due to gain-of-function variants (Fig. 3A) [54]. Here, TTR is linked to amyloidosis.